Lighter chemo with immunotherapy for triple-negative breast cancer
Part of Cancer, Skin clinical trials.
This trial tests whether using less chemotherapy combined with immunotherapy before surgery works well for people with stage II or III triple-negative breast cancer. The goal is to reduce side effects while still being effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have triple-negative breast cancer diagnosed by biopsy at Peking University People's Hospital.
- Your cancer must be stage II or III (tumor size T2 or larger and/or cancer has spread to nearby lymph nodes, but not to distant organs).
- You must have received treatment and have hospitalization records at Peking University People's Hospital.
- You must agree to join the breast disease cohort study at the same hospital.
- You cannot have metastatic or bilateral breast cancer, or be in other anti-cancer clinical trials.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a combination of chemotherapy drugs (nab-paclitaxel and carboplatin) plus an immunotherapy drug (PD1 inhibitor) given before surgery can help treat early-stage triple-negative breast cancer. It aims to improve outcomes by using these treatments before the main surgery.
This trial tests a new combination of chemotherapy and immunotherapy that avoids a class of drugs called anthracyclines, which can be hard on the heart. The goal is to shrink tumors before surgery for people with triple-negative or low-hormone-receptor breast cancer.
This trial tests whether giving pembrolizumab (an immunotherapy drug) together with chemotherapy before surgery can help treat early-stage triple-negative breast cancer. It aims to improve outcomes by shrinking the tumor before removal.
This trial tests a combination of an immunotherapy drug (pembrolizumab) plus two chemotherapy drugs (carboplatin and paclitaxel) given before surgery for people with early-stage, triple-negative breast cancer. The goal is to see if this treatment helps shrink or eliminate the tumor before it's removed.
This trial tests whether adding an immunotherapy drug (HLX10) to chemotherapy before surgery, and then continuing it after surgery, helps people with triple-negative breast cancer more than chemotherapy alone. It is a type of breast cancer that does not respond to hormone treatments or HER2-targeted treatments.
This study looks at whether using targeted therapy can reduce the amount of chemotherapy needed before surgery for HER2-positive breast cancer. It aims to find a safer, equally effective treatment plan.
Hear when a new Triple Negative Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.